Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders
Description
Disorders characterized by proliferation of lymphoid tissue, general or unspecified. MeSH
Hierarchy View
Subtype Terms (21)
Agammaglobulinemia
24 drugs (21 approved, 3 experimental)
Autoimmune Lymphoproliferative Syndrome
5 approved drugs
Castleman Disease
22 drugs (20 approved, 2 experimental)
Granuloma
38 drugs (29 approved, 9 experimental)
Immunoblastic Lymphadenopathy
1 approved drug
Immunoglobulin Light-chain Amyloidosis
51 drugs (40 approved, 11 experimental)
Immunoproliferative Small Intestinal Disease
Infectious Mononucleosis
7 drugs (4 approved, 3 experimental)
Leukemia, Hairy Cell
87 drugs (61 approved, 26 experimental)
Leukemia, Lymphoid
135 drugs (80 approved, 55 experimental)
Lymphangiomyoma
1 approved drug
Lymphoma
936 drugs (373 approved, 563 experimental)
Macrophage Activation Syndrome
8 drugs (7 approved, 1 experimental)
Multiple Myeloma
836 drugs (293 approved, 543 experimental)
Plasmacytoma
84 drugs (59 approved, 25 experimental)
Sarcoidosis
53 drugs (40 approved, 13 experimental)
Sezary Syndrome
121 drugs (80 approved, 41 experimental)
Tumor Lysis Syndrome
4 approved drugs
Waldenstrom Macroglobulinemia
168 drugs (94 approved, 74 experimental)
Approved Indicated Drugs (1)
Phase 2 Indicated Drugs (47)
allogeneic hematopoietic stem cells (Hemacord)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous hematopoietic stem cells
autologous immunoglobulin idiotype-klh conjugate vaccine
Phase 1 Indicated Drugs (24)
Other Experimental Indicated Drugs (9)
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (17)
Organization Involved with Phase 2 Indications (48)
Korea Research Institute of Bioscience & Biotechnology
Methodist Cancer Center, Houston, Texas
State University of New York, Buffalo
The University of Texas, Dallas
University of California, San Diego
Organization Involved with Phase 1 Indications (21)
Organization Involved with Other Experimental Indications (4)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
